TD Cowen raised the firm’s price target on Roivant Sciences (ROIV) to $41 from $38 and keeps a Buy rating on the shares. The firm said IMVT-1402 toplined impressive Ph2b D2T RA data with ACR20 of 73%, ACR50 of 55%, and ACR70 of 36%. Cowen said there are many more catalysts on deck.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV: